1. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park B, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders P, Wallis R, Weaver R, York M, Valentin J. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Cardiovascular toxicity of medicines. Br J Pharmacol. 2011;163:675–93. https://doi.org/10.1111/j.1476-5381.2011.01255.x.
2. ICH E14. ICH E14. Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; 2005. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-14-clinical-evaluation-qt/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf. Accessed 1 March 2022.
3. ICH 2005. Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation. Accessed 1 March 2022.
4. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0004.html. Accessed 1 March 2022.
5. Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10. https://doi.org/10.1002/pds.668.